Sanjay Popat

1999–2026 年に発表

155
論文数
26,009
被引用数
58
h 指数
139
i10 指数

被引用数

Sanjay Popat の年別被引用数1993 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 4 件2003 年: 被引用 5 件2004 年: 被引用 1 件2005 年: 被引用 19 件2006 年: 被引用 21 件2007 年: 被引用 19 件2008 年: 被引用 37 件2009 年: 被引用 47 件2010 年: 被引用 67 件2011 年: 被引用 66 件2012 年: 被引用 48 件2013 年: 被引用 68 件2014 年: 被引用 74 件2015 年: 被引用 100 件2016 年: 被引用 147 件2017 年: 被引用 144 件2018 年: 被引用 175 件2019 年: 被引用 849 件2020 年: 被引用 1,132 件2021 年: 被引用 1,341 件2022 年: 被引用 1,036 件2023 年: 被引用 850 件2024 年: 被引用 1,572 件2025 年: 被引用 839 件2026 年: 被引用 18 件1994〜2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,231 件、この内訳の 17.2%中国: 引用元論文 1,509 件、この内訳の 11.7%イタリア: 引用元論文 1,006 件、この内訳の 7.8%イギリス: 引用元論文 886 件、この内訳の 6.9%フランス: 引用元論文 702 件、この内訳の 5.4%ドイツ: 引用元論文 604 件、この内訳の 4.7%スペイン: 引用元論文 598 件、この内訳の 4.6%日本: 引用元論文 560 件、この内訳の 4.3%オランダ: 引用元論文 455 件、この内訳の 3.5%スイス: 引用元論文 374 件、この内訳の 2.9%カナダ: 引用元論文 364 件、この内訳の 2.8%韓国: 引用元論文 355 件、この内訳の 2.7%
0%17.2%その他 25.5%

分野

  • Medicine78.1%
  • Biochemistry, Genetics and Molecular Biology17.1%
  • Immunology and Microbiology1.8%
  • Computer Science0.6%
  • Engineering0.5%
  • Agricultural and Biological Sciences0.4%
  • その他1.5%

トピック

  • Lung Cancer Treatments and Mutations14.5%
  • Cancer Immunotherapy and Biomarkers8.3%
  • Lung Cancer Research Studies7.7%
  • Lung Cancer Diagnosis and Treatment6.1%
  • Cancer Genomics and Diagnostics5.2%
  • Colorectal Cancer Treatments and Studies3.3%
  • その他54.9%

共著者

全論文

検索で開く
  1. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 664

  2. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi - Annals of Oncology 2019 被引用: 1,361

  3. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet 2021 被引用: 1,194

  4. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , - Annals of Oncology 2018 被引用: 2,299

  5. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Angela Girvin, James Greger, Dawn Millington, Monica Withelder, John Xie, Tao Sun, Shalin Shah, B. Diorio, Roland E. Knoblauch, Joshua Bauml, Rosario García Campelo, Byoung Chul Cho - Annals of Oncology 2023 被引用: 396

  6. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 347

  7. RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emilia L. Lim, Mark S. Hill, Gareth A. Wilson, Daniel E. Cook, Nicolai J. Birkbak, Axel Behrens, Nadia Yousaf, Sanjay Popat, Allan Hackshaw, Andrew Rowan, Ariana Huebner, Brittany Campbell, Chris Bailey, Claudia Lee, Dhruva Biswas, Emma Colliver, Foteini Athanasopoulou, Hao-Ran Zhai, Jayant K. Rane, Kristiana Grigoriadis, Michelle Dietzen, Michelle Leung, Mihaela Angelova, Olivia Lucas, Othman Al‐Sawaf, Rachel Rosenthal, Jérôme Nicod, Abigail Bunkum, Antonia Toncheva, Christopher Abbosh, Corentin Richard, Cristina Naceur‐Lombardelli, Francisco Gimeno-Valiente, Jie Min Lam, Kerstin Thol, Krupa Thakkar, Mariana Werner Sunderland, Martin Förster, Nnennaya Kanu, Paulina Prymas, Robert B. Bentham, Sadegh Saghafinia, Sergio A. Quezada, Sharon Vanloo, Simone Zaccaria, Siow Ming Lee, Sonya Hessey, Wing Kin Liu, Dionysis Papadatos-Pastos, James M. Wilson, Sarah Benafif, Tanya Ahmad, Elaine Borg, Mary Falzon, Reena Khiroya, Teresa Marafioti, Abigail Sharp, Camilla Pilotti, Harjot Kaur Dhanda, Kitty S. Chan, Nicole Gower, Rachel Leslie, Sean Smith, Andrew G. Nicholson, Eric Lim, Javier Herrero, Carla Castignani, Elizabeth Larose Cadieux, Jonas Demeulemeester, Peter Van Loo ほか 231 名 - Nature 2023 被引用: 249

  8. Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 976

  9. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , - Annals of Oncology 2016 被引用: 2,636

  10. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2021 被引用: 372

  11. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 263

  12. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory E. Sims, Yong Yuan, Byoung Chul Cho - New England Journal of Medicine 2024 被引用: 210

  13. Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis

    著者: , , - Journal of Clinical Oncology 2005 被引用: 1,828

  14. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michiel Strijbos, Sanjay Popat, Piet Ost, Matthias Gückenberger - The Lancet Oncology 2023 被引用: 172

  15. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 1,580

  16. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 367

  17. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 被引用: 131

  18. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sabine Bohnet, Ekaterini Boleti, Hossein Borghaei, Penelope A. Bradbury, Matteo Brighenti, Nicholas Campbell, Toby Campbell, Jean-Luc Canon, Federico Cappuzzo, Enric Carcereny Costa, Luigi Cavanna, Jeremy Cetnar, Antonio Chella, C. Chouaïd, Daniel C. Christoph, J. Cortés Castán, Shaker R. Dakhil, F.J. de Castro Carpeño, Filippo de Marinis, Angelo Delmonte, Ingel Demedts, Wim Demey, Joyce Dits, Maria del Pilar Diz Taín, M. Dómine Gómez, Timothy Dorius, Daphne W. Dumoulin, M. Duruisseaux, Keith D. Eaton, Emilio Esteban González, Devon Evans, Martin Faehling, Nicholas Farrell, Trevor Feinstein, E. Felip Font, M.R. García Campelo, Edward B. Garon, María Pilar Garrido López, Paul Germonpré, Todd Gersten, María González Cao, Srivalli Gopaluni, Laurent Greillier, Francesco Grossi, Florian Guisier, Sarada Gurubhagavatula, Vanesa Gutiérrez Calderón, David Hakimian, Richard D. Hall, Desirée Hao, Ronald Harris, Sayed M.S. Hashemi, Kai He, Lizza Hendriks, Chao Huang, Emad Ibrahim, Sharad Jain, Melissa L. Johnson, B. J. P. Jones, Monte Jones, Óscar Juan, Rosalyn A. Juergens, Courèche Kaderbhaï, Elisabeth A. Kastelijn, Roger Keresztes, Ebenezer A. Kio, Konrad Kokowski, Kartik Konduri, Swati Kulkarni, Jonas Kuon ほか 84 名 - Annals of Oncology 2023 被引用: 93

  19. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Chih‐Hsin Yang, Yasushi Yatabe, George Pentheroudakis, Solange Peters - Annals of Oncology 2022 被引用: 190

  20. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

    著者: , , , , , - Journal of Thoracic Oncology 2020 被引用: 213

  21. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 56

  22. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 273

  23. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anita Hiltbrunner, Mariana Pardo-Contreras, A. Gasca-Ruchti, Nino Giacomelli, Roswitha Kammler, Nesa Marti, Rita Pfister, Anne‐Christine Piguet, Susanne Roux, Sandra Troesch, M. Schneider, Robin Schweri, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, S. Tsouprou, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Franck Morin, Elodie Amour, G. Mariaule, N. Archirel, María Dolores Arnaiz Fernández, E. Pereira, M. Fernandez, K. Lopez, Ainhoa Hernández, Sarah Chinchen, H. Jurkovic, Alan S. Livingstone, Jerry W. Mitchell, Macie B. Walker, Paul Mitchell, S. Ng, Christopher Steer, Karen Briscoe, Amina Saqib, Ehtesham Abdi, Baerin Houghton, Kenneth J. O’Byrne, B.R. Chittajallu, Brett Hughes, A. Black, Kristiaan Nackaerts, Henrica M.J. Werner, R. Gervais, Gérard Zalcman, F. Vaylet, P. Merle, I. Monnet, Denis Moro‐Sibilot, Olivier Molinier, Nicolas Girard, P.-J. Souquet, Fabrice Barlési, D. Debieuvre, Hélène Senellart, M. Poudenx, A. Dixmier, Damien Pouessel, Jacques Cadranel, H. Léna, Élisabeth Quoix, S. Friard, Clarisse Audigier-Valette, Julien Mazières, Éric Pichon, Martin Faehling ほか 20 名 - Annals of Oncology 2021 被引用: 114

  24. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

    著者: , , , , , , , , - Annals of Oncology 2021 被引用: 227